Arrowhead Pharmaceuticals, Inc.
http://arrowheadpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arrowhead Pharmaceuticals, Inc.
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Sanofi Ramps Up In Rare Diseases With Inhibrx Buy
The French major is paying up to $2.2bn to get access to Inhibrx’s alpha-1 antitrypsin deficiency candidate and to take a stake in the rest of the California-based biotech’s portfolio.
Stock Watch: Fewer Acquisitions Leave Many Behind
The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.
Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast
Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Ablaris Therapeutics, Inc.
- Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
- Arrowhead Research Corporation
- Calando Pharmaceuticals, Inc.
- Unidym
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice